Literature DB >> 34860154

Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021.

Haogao Gu, Pavithra Krishnan, Daisy Y M Ng, Lydia D J Chang, Gigi Y Z Liu, Samuel S M Cheng, Mani M Y Hui, Mathew C Y Fan, Jacob H L Wan, Leo H K Lau, Benjamin J Cowling, Malik Peiris, Leo L M Poon.   

Abstract

We report detection of severe acute respiratory syndrome coronavirus 2 Omicron variant (B.1.1.529) in an asymptomatic, fully vaccinated traveler in a quarantine hotel in Hong Kong, China. The Omicron variant was also detected in a fully vaccinated traveler staying in a room across the corridor from the index patient, suggesting transmission despite strict quarantine precautions.

Entities:  

Keywords:  COVID-19; China; Hong Kong; Omicron variant B.1.1.529; SARS-CoV-2; coronavirus disease; coronaviruses¸ viruses; quarantine hotel; respiratory infections; severe acute respiratory syndrome coronavirus 2; transmission; variant of concern; zoonoses

Mesh:

Year:  2021        PMID: 34860154      PMCID: PMC8798678          DOI: 10.3201/eid2802.212422

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


A new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), B.1.1.529, was identified in Botswana and South Africa in early November 2021 and was designated as variant of concern (VOC) Omicron by the World Health Organization on November 26, 2021 (). As of December 1, 2021, ≈220 sequences were available on GISAID (https://www.gisaid.org), and this variant has been detected in countries in Africa and beyond since mid-November (,). This variant contains >30 spike protein amino acid mutations that might be associated with increased transmissibility, severity, and capacity for immune escape. With supporting evidence of epidemiologic and molecular epidemiologic findings, we report the probable transmission of Omicron in a quarantine hotel in Hong Kong, China. We also compare its mutational profile with other VOCs and variants of interest. Two cases of infection with VOC Omicron (cases A and B) were detected in Hong Kong. Case-patient A arrived in Hong Kong from South Africa on November 11, 2021, and case-patient B arrived in Hong Kong from Canada on November 10, 2021. Both case-patients had previously received 2 vaccine doses (Pfizer-BioNTech, https://www.pfizer.com); the second dose was given on June 4, 2021, for case-patient A and on May 25, 2021, for case-patient B. Both case-patients tested negative by reverse transcription PCR (RT-PCR) for SARS-CoV-2 within 72 hours before arrival. On arrival at the Hong Kong airport, both case-patients stayed in the same quarantine hotel and had rooms across the corridor from each other on the same floor. Case-patient A showed a positive result for SARS-CoV-2 without symptoms on November 13, 2021 (cycle threshold [Ct] value 18). He was hospitalized and isolated the next day. Case-patient B had mild symptoms develop on November 17, 2021. He showed a positive result for SARS-CoV-2 (Ct value 19) on November 18, 2021, and was hospitalized on the same day. The 2 Ct values indicate high viral loads. None of the 12 persons staying in nearby rooms on the same floor during the study or related hotel staff have tested positive in repeated tests for SARS-CoV-2 (). Viral genomes deduced from these 2 SARS-CoV-2‒positive cases differed only by 1 nt. Retrospective investigation, including closed-circuit television camera footage, confirmed that neither case-patient left their room during the quarantine period. No items were shared between rooms, and other persons did not enter either room. The only time the 2 quarantined persons opened their respective doors was to collect of food that was placed immediately outside each room door. The only other time they might have opened their doors would be for RT-PCRs, which were conducted in 3-day intervals. However, because these 2 case-patients arrived 1 day apart, it is unlikely that they would be tested on the same day. Airborne transmission across the corridor is the most probable mode of transmission. We sequenced complete SARS-CoV-2 genomes from case-patients A and B (Appendix) and confirmed that these genomes were VOC Omicron (Pango lineage B.1.1.529) (Figure, panel A). Viral sequences from these 2 case-patients differed by only 1 nt. Viral sequence from case-patient A was highly similar to those of the first few reported Omicron cases identified in South Africa and Botswana (Appendix Table 1). Because many countries have just reported detection of this VOC (https://www.gisaid.org/hcov19-variants), the actual genetic diversity of this virus lineage requires further investigations.
Figure

Detection of severe acute respiratory syndrome coronavirus 2 Omicron variant in 2 patients (cases A and B) in Hong Kong, China, November 2021. A) Phylogenetic time tree of Omicron nucleotide sequences using an early severe acute respiratory syndrome coronavirus sequence as a reference sequence (Wuhan-Hu-1/2019; GenBank accession no. MN908947.3). B) Comparison of Omicron variant mutations in case A to other variants; red indicates VOC and gray VOI (Appendix). Text colors indicate mutations found in NTD (blue), RBD (orange), FP (purple), and HR1 (green). Lane 1, case A; 2, Alpha (B.1.1.7); 3, Beta (B.1351); 4, Delta (B.1.617.2); 5, Gamma (P1); 6, Epsilon (B.1.427/429); 7, Eta (B.1.525); 8, Iota (B.1.526); 9, Kappa (B.1.617.1); 10, Lambda (C.37); 11, Mu (B.1.1.621); 12, Theta (P.3); 13, Zeta (P.2). E, envelope; FP, fusion peptide; HR1, heptad repeat 1; M, matrix; NSP, nonstructural protein; NTD, N-terminal domain; RBD, receptor-binding domain; S, spike; VOC, variant of concern; VOI, variant of interest.

Detection of severe acute respiratory syndrome coronavirus 2 Omicron variant in 2 patients (cases A and B) in Hong Kong, China, November 2021. A) Phylogenetic time tree of Omicron nucleotide sequences using an early severe acute respiratory syndrome coronavirus sequence as a reference sequence (Wuhan-Hu-1/2019; GenBank accession no. MN908947.3). B) Comparison of Omicron variant mutations in case A to other variants; red indicates VOC and gray VOI (Appendix). Text colors indicate mutations found in NTD (blue), RBD (orange), FP (purple), and HR1 (green). Lane 1, case A; 2, Alpha (B.1.1.7); 3, Beta (B.1351); 4, Delta (B.1.617.2); 5, Gamma (P1); 6, Epsilon (B.1.427/429); 7, Eta (B.1.525); 8, Iota (B.1.526); 9, Kappa (B.1.617.1); 10, Lambda (C.37); 11, Mu (B.1.1.621); 12, Theta (P.3); 13, Zeta (P.2). E, envelope; FP, fusion peptide; HR1, heptad repeat 1; M, matrix; NSP, nonstructural protein; NTD, N-terminal domain; RBD, receptor-binding domain; S, spike; VOC, variant of concern; VOI, variant of interest. The long branch of Omicron clade in the phylogenetic tree is attributed to the large number of mutations (Figure, panel A). Nonsynonymous mutations were identified in the spike (S)‒encoding (n = 35) and other viral protein‒encoding (n = 22) regions (Figure, panel B). Among the nonsynonymous mutations in the S protein, 43% (n = 15) were also identified in other VOCs/variants of interest, and 31% (n = 11) were found only in VOCs (Alpha, n = 6; Beta, n = 4; Gamma, n = 5; Delta, n = 4). Some of the point mutations and deletions found in other regions are not novel and can also be found in other variants at different frequencies (Appendix Table 2). Among these non-S mutations, NSP4-T492I, NSP6-S106del, NSP6-G107del, NSP12-P323L, N-P13L, N-R203K, and N-G204R are commonly found in SARS-CoV-2 variants. The laboratory and epidemiologic features of the Omicron variant are yet to be fully characterized and cannot be determined on the basis of sequence features alone. Nonetheless, compared with other VOCs, the number of mutations found in the spike of the Omicron variant is unprecedented. This finding results in false-negative results in some diagnostic RT-PCRs specific for the S gene (). Many of the mutations found in the S protein are known to alter SARS-CoV-2 antigenicity and transmissibility (). The R203K and G204R mutations in the nucleocapsid protein are also associated with enhanced virus replication (). It is not known whether these detected mutations might have affected the effectiveness of existing vaccines and virus transmissibility. However, detection of Omicron variant transmission between 2 fully vaccinated persons across the corridor of a quarantine hotel has highlighted this potential concern. Further experimental characterizations and epidemiologic investigations of this newly found VOC are urgently needed. Increased precautions or additional measures might be warranted while awaiting more data.

Appendix

Additional information on probable transmission of SARS-CoV-2 omicron variant in quarantine hotel, Hong Kong, China, November 2021.
  3 in total

1.  Heavily mutated Omicron variant puts scientists on alert.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2021-12       Impact factor: 49.962

Review 2.  The biological and clinical significance of emerging SARS-CoV-2 variants.

Authors:  Kaiming Tao; Philip L Tzou; Janin Nouhin; Ravindra K Gupta; Tulio de Oliveira; Sergei L Kosakovsky Pond; Daniela Fera; Robert W Shafer
Journal:  Nat Rev Genet       Date:  2021-09-17       Impact factor: 53.242

3.  Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2.

Authors:  Haibo Wu; Na Xing; Kaiwen Meng; Beibei Fu; Weiwei Xue; Pan Dong; Wanyan Tang; Yang Xiao; Gexin Liu; Haitao Luo; Wenzhuang Zhu; Xiaoyuan Lin; Geng Meng; Zhenglin Zhu
Journal:  Cell Host Microbe       Date:  2021-11-13       Impact factor: 21.023

  3 in total
  54 in total

1.  Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host-pathogen interaction, pathogenicity, and possible drug therapeutics.

Authors:  Md Sorwer Alam Parvez; Manash Kumar Saha; Md Ibrahim; Yusha Araf; Md Taufiqul Islam; Gen Ohtsuki; Mohammad Jakir Hosen
Journal:  Immun Inflamm Dis       Date:  2022-07

2.  Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron.

Authors:  Anne-Cathrine S Vogt; Gilles Augusto; Byron Martina; Xinyue Chang; Gheyath Nasrallah; Daniel E Speiser; Monique Vogel; Martin F Bachmann; Mona O Mohsen
Journal:  Vaccines (Basel)       Date:  2022-05-09

3.  The impact of the Omicron epidemic on the health behavior in Cape Town, South Africa.

Authors:  Xiao-Qing Lin; Li Lv; Yan Chen; He-Dan Chen; Mei-Xian Zhang; Tao-Hsin Tung; Jian-Sheng Zhu
Journal:  One Health       Date:  2022-05-05

4.  Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529.

Authors:  Jency Roshni; R Vaishali; K S Ganesh; N Dharani; Khalid J Alzahrani; Hamsa Jameel Banjer; Ali H Alghamdi; Abdulrahman Theyab; Shiek Ssj Ahmed; Shankargouda Patil
Journal:  J Infect Public Health       Date:  2022-05-13       Impact factor: 7.537

5.  Low testing rates limit the ability of genomic surveillance programs to monitor SARS-CoV-2 variants: a mathematical modelling study.

Authors:  Alvin X Han; Amy Toporowski; Jilian A Sacks; Mark Perkins; Sylvie Briand; Maria van Kerkhove; Emma Hannay; Sergio Carmona; Bill Rodriguez; Edyth Parker; Brooke E Nichols; Colin A Russell
Journal:  medRxiv       Date:  2022-05-23

6.  Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.

Authors:  Shankargouda Patil; Khalid J Alzahrani; Hamsa Jameel Banjer; Ibrahim Faisal Halawani; Hosam Alzahrani; Malik A Altayar; Sarah Albogami; Robert Fua Angeles; Ali Abdel-Halim Abdel-Azim Hassan; Shilpa Bhandi; A Thirumal Raj
Journal:  J Infect Public Health       Date:  2022-06-16       Impact factor: 7.537

7.  SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.

Authors:  Kenrie P Y Hui; John C W Ho; Man-Chun Cheung; Ka-Chun Ng; Rachel H H Ching; Ka-Ling Lai; Tonia Tong Kam; Haogao Gu; Ko-Yung Sit; Michael K Y Hsin; Timmy W K Au; Leo L M Poon; Malik Peiris; John M Nicholls; Michael C W Chan
Journal:  Nature       Date:  2022-02-01       Impact factor: 49.962

8.  Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.

Authors:  Koichi Furukawa; Lidya Handayani Tjan; Yukiya Kurahashi; Silvia Sutandhio; Mitsuhiro Nishimura; Jun Arii; Yasuko Mori
Journal:  JAMA Netw Open       Date:  2022-05-02

9.  Omicron variant in the current SARS-CoV-2 pandemic.

Authors:  Kaveh Nasiri; Aleksandra Dimitrova
Journal:  J Dent Sci       Date:  2022-01-19       Impact factor: 3.719

10.  Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021.

Authors:  Ji Joo Lee; Young June Choe; Hyeongseop Jeong; Moonsu Kim; Seonggon Kim; Hanna Yoo; Kunhee Park; Chanhee Kim; Sojin Choi; JiWoo Sim; Yoojin Park; In Sil Huh; Gasil Hong; Mi Young Kim; Jin Su Song; Jihee Lee; Eun-Jin Kim; Jee Eun Rhee; Il-Hwan Kim; Jin Gwack; Jungyeon Kim; Jin-Hwan Jeon; Wook-Gyo Lee; Suyeon Jeong; Jusim Kim; Byungsik Bae; Ja Eun Kim; Hyeonsoo Kim; Hye Young Lee; Sang-Eun Lee; Jong Mu Kim; Hanul Park; Mi Yu; Jihyun Choi; Jia Kim; Hyeryeon Lee; Eun-Jung Jang; Dosang Lim; Sangwon Lee; Young-Joon Park
Journal:  J Korean Med Sci       Date:  2021-12-27       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.